Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLL1:TRAIL
- Development stage
- Preclinical
- Lead developer
- University Medical Center Groningen
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
CLL1:TRAIL (also known as scFvCLL1:TRAIL) is a recombinant fusion protein biologic designed to enhance the tumoricidal activity of granulocytes. It consists of a single-chain variable fragment (scFv) antibody targeting the myeloid marker C-type lectin-like molecule-1 (CLL1/CLEC12A) fused to the extracellular domain of the pro-apoptotic protein tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). The mechanism involves selectively binding to CLL1 on the surface of granulocytes and monocytes, thereby "arming" these immune effector cells with high levels of membrane-associated TRAIL. This allows the leukocytes to trigger apoptosis in cancer cells via TRAIL receptors (DR4 and DR5) and significantly potentiates the antibody-dependent cell-mediated cytotoxicity (ADCC) of therapeutic monoclonal antibodies such as rituximab and cetuximab. It is primarily investigated as an adjuvant to optimize anticancer antibody therapies.
- Other names
- CLL1 + TRAILCLL1-TRAILCLL-1-TRAILCLL 1-TRAILscFvCLL1-sTRAILscFvCLL-1-sTRAILscFvCLL 1-sTRAIL
02
Targets
TNFRSF10B (DR5)TNFRSF10A (Death receptor 4)CLEC12A
Beyond the preview
Go deeper on CLL1:TRAIL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLL1:TRAIL.